Results from the SHORTEN study demonstrate safety and tolerability of accelerated 20-minute agalsidase beta infusions in patients with Fabry disease

Background Agalsidase beta is an enzyme replacement therapy for Fabry disease (FD) administered as a 1 mg/kg biweekly infusion over 90–120 minutes. The present study evaluated the safety and tolerability of a shortened 20-minute infusion duration, with pharmacokinetic simulations conducted to assess systemic exposure at accelerated infusion rates. Methods The SHORTEN study (NCT06019728) was a phase 4, prospective, open-label, single-arm trial. Eight patients were enrolled (5 male, 3 female; age 19–62 years) with confirmed diagnosis of FD, body weight ≥ 30 kg, and history of agalsidase beta therapy for ≥3 months without infusion-associated reactions (IARs). Infusion duration was progressively reduced by 20- or 30- minute increments until reaching 20 minutes, using a standardized 100 mL infusion volume. Primary endpoints were percentage reduction in infusion duration versus baseline and the shortest tolerated duration. Secondary endpoints included the proportion of patients achieving the shortest planned duration without IARs. A linear two-compartment model was developed using clinical trial data (21 patients; 1547 samples) for population pharmacokinetic (PopPK) simulation analysis. Simulations included 1 mg/kg dosing with 20- versus 120-minute infusion durations in 1,000 virtual participants. Maximum plasma concentration (C max ) and area under the curve (AUC) were evaluated within 24-hours after each dose. Results All participants achieved 20-minute infusion duration (median reduction 84.2%; IQR: 80.6%–86.3%) with no IARs reported. Treatment-emergent adverse events of moderate intensity were reported in two participants, with none considered treatment-related. Globotriaosylsphingosine levels (lyso-GL-3) remained stable, except for a transient small increase in one patient after a missed infusion. One participant had pre-existing low-titer anti-drug antibodies (ADAs), without any treatment-induced or treatment-boosted ADA responses observed. PopPK simulations demonstrated that shortening the infusion duration from 120 to 20 minutes approximately doubled the C max (8.18 vs. 3.86 μg/mL), while preserving equivalent AUC (857.02 μg/mL×min). Conclusions The SHORTEN study demonstrated that agalsidase beta can be safely administered over 20 minutes in carefully selected, treatment-experienced patients with FD. PopPK simulations support the acceptability of the shortened infusion duration, indicating comparable overall drug exposure with a clinically acceptable peak concentration profile. This accelerated infusion approach has the potential to reduce treatment burden while maintaining tolerability and therapeutic activity. Trial registration number ClinicalTrials.gov, NCT06019728. Registered 25 August 2023, https://clinicaltrials.gov/study/NCT06019728

Authors

Institutions

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-19
DOI
https://doi.org/10.1186/s13023-026-04729-0
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Results from the SHORTEN study demonstrate safety and tolerability of accelerated 20-minute agalsidase beta infusions in patients with Fabry disease

Manish R. Maski, William Ross Wilcox, Jasminder Sahi, Mrinalini Sarkar et al.
Orphanet Journal of Rare Diseases
Lysosomal Storage Disorders Research
article

Results from the SHORTEN study demonstrate safety and tolerability of accelerated 20-minute agalsidase beta infusions in patients with Fabry disease

Manish R. Maski, William Ross Wilcox, Jasminder Sahi, Mrinalini Sarkar, Maryam Banikazemi, Chae Sung Lee, Kunal Jhunjhunwala, Özlem Göker-Alpan, Kenneth I. Berger, K. Nedd, Malidi Ahamadi, Shuai Shao
article en

Abstract

Background Agalsidase beta is an enzyme replacement therapy for Fabry disease (FD) administered as a 1 mg/kg biweekly infusion over 90–120 minutes. The present study evaluated the safety and tolerability of a shortened 20-minute infusion duration, with pharmacokinetic simulations conducted to assess systemic exposure at accelerated infusion rates. Methods The SHORTEN study (NCT06019728) was a phase 4, prospective, open-label, single-arm trial. Eight patients were enrolled (5 male, 3 female; age 19–62 years) with confirmed diagnosis of FD, body weight ≥ 30 kg, and history of agalsidase beta therapy for ≥3 months without infusion-associated reactions (IARs). Infusion duration was progressively reduced by 20- or 30- minute increments until reaching 20 minutes, using a standardized 100 mL infusion volume. Primary endpoints were percentage reduction in infusion duration versus baseline and the shortest tolerated duration. Secondary endpoints included the proportion of patients achieving the shortest planned duration without IARs. A linear two-compartment model was developed using clinical trial data (21 patients; 1547 samples) for population pharmacokinetic (PopPK) simulation analysis. Simulations included 1 mg/kg dosing with 20- versus 120-minute infusion durations in 1,000 virtual participants. Maximum plasma concentration (C max ) and area under the curve (AUC) were evaluated within 24-hours after each dose. Results All participants achieved 20-minute infusion duration (median reduction 84.2%; IQR: 80.6%–86.3%) with no IARs reported. Treatment-emergent adverse events of moderate intensity were reported in two participants, with none considered treatment-related. Globotriaosylsphingosine levels (lyso-GL-3) remained stable, except for a transient small increase in one patient after a missed infusion. One participant had pre-existing low-titer anti-drug antibodies (ADAs), without any treatment-induced or treatment-boosted ADA responses observed. PopPK simulations demonstrated that shortening the infusion duration from 120 to 20 minutes approximately doubled the C max (8.18 vs. 3.86 μg/mL), while preserving equivalent AUC (857.02 μg/mL×min). Conclusions The SHORTEN study demonstrated that agalsidase beta can be safely administered over 20 minutes in carefully selected, treatment-experienced patients with FD. PopPK simulations support the acceptability of the shortened infusion duration, indicating comparable overall drug exposure with a clinically acceptable peak concentration profile. This accelerated infusion approach has the potential to reduce treatment burden while maintaining tolerability and therapeutic activity. Trial registration number ClinicalTrials.gov, NCT06019728. Registered 25 August 2023, https://clinicaltrials.gov/study/NCT06019728

Orphanet Journal of Rare Diseases
Emory University (US), University of California, Los Angeles (US), Metropolitan Hospital Center (US), Lysosomal and Rare Disorders Research and Treatment Center (US), Infusion Associates (US), Vertex Pharmaceuticals (United States) (US)
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon